Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

Michigan Advanced Psychiatry pioneers FDA-approved neuromodulation therapies like TMS, IV ketamine, and Spravato to treat resistant mental health conditions, offering fast, effective alternatives for ...

For work identifying a novel therapeutic target to improve walking after SCI, Newton Cho is the 2025 winner of the Science & PINS Prize for Neuromodulation. The prize rewards innovative research that ...

Nature is often the best model for science. For nearly a century, scientists have been trying to recreate the ability of some ...

Looking for the latest stock opportunities in August 2025? Click to read these top stock picks to consider adding to your ...

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and ...

Understanding mental illness requires understanding psychiatric disorder causality. New brain research explores this in ...

DBS involves an implanted device that delivers electrical current directly to different areas of the brain, giving them a ...

Audrey Crews, paralysed for two decades, has achieved a groundbreaking feat by controlling a computer cursor and signing her ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

Urinary incontinence is a devastating condition affecting over 33 million Americans, according to the National Association ...